EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso
Executive Summary
The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.
You may also be interested in...
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO argues, since payers will still be under pressure.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.
EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.